<bill session="118" type="s" number="1131" updated="2025-04-21T12:24:17Z">
  <state datetime="2023-03-30">REFERRED</state>
  <status>
    <introduced datetime="2023-03-30"/>
  </status>
  <introduced datetime="2023-03-30"/>
  <titles>
    <title type="display">Drug Price Transparency Act of 2023</title>
    <title type="short" as="introduced">Drug Price Transparency Act of 2023</title>
    <title type="official" as="introduced">A bill to amend title XI of the Social Security Act and title XXVII of the Public Health Service Act to establish requirements with respect to prescription drug benefits.</title>
  </titles>
  <sponsor bioguide_id="B001310"/>
  <cosponsors>
    <cosponsor bioguide_id="H001079" joined="2023-03-30"/>
  </cosponsors>
  <actions>
    <action datetime="2023-03-30">
      <text>Introduced in Senate</text>
    </action>
    <action datetime="2023-03-30" state="REFERRED">
      <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text>
    </action>
  </actions>
  <committees>
    <committee code="SSHR" name="Senate Health, Education, Labor, and Pensions" subcommittee="" activity="Referred To"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Health"/>
  </subjects>
  <amendments/>
  <summary date="2023-10-31T19:01:57Z" status="Introduced in Senate">Drug Price Transparency Act of 2023

This bill provides statutory authority for the limitation on which type of prescription drug rebates are exempt from federal anti-kickback laws. Specifically, a rebate from a drug manufacturer to a health insurer or pharmacy benefit manager is exempt only if the rebate (1) is disclosed to the consumer at the point of sale, or (2) is a flat fee paid for pharmacy benefit management services.</summary>
</bill>
